Abivax SA
(NASDAQ: ABVX)
|
5:00 PM UTC, 07/03/24 | |||
---|---|---|---|---|
Last: $13.07 | Change: -0.43 | %Change: -3.19% | Volume: 8,262 |
Open: | $ 13.54 | Volume: | 8,262 | |
---|---|---|---|---|
High: | $ 13.54 | Yield(%) | 0.00 | |
Low: | $ 13.03 | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | 849.39M | |
EPS ($) | n/a | Shares Out: | 62.92M |
% Price Change (last 4 weeks): | 1.28 |
---|---|
% Price Change (last 13 weeks): | -3.85 |
% Price Change (last 26 weeks): | 25.00 |
% Price Change (last 52 weeks): | n/a |
% Price Change (year to date): | 26.17 |
Return on Equity (%): | -146.18 |
---|---|
Return on Assets (%): | -72.67 |
Return on Invested Capital (%): | -101.92 |
Gross Profit Margin (%): | n/a |
---|---|
Net Profit Margin (%): | n/a |
Operating Profit Margin (%): | 0.00 |
|
|
50-day Moving Average: | $14.10 |
---|---|
200-day Moving Average: | $n/a |
Avg. Daily Vol. (last 50 days): | 46,307 |
Avg. Daily Vol. (last 200 days): | n/a |
52-wk high: | $n/a |
52-wk low: | $n/a |
Bid: | $13.01 |
Ask: | $21.28 |
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.
|
Abivax SA
7-11 Boulevard Haussmann Paris IF 75009 Phone: 33.1.53.83.09.63 Fax: n/a http://www.abivax.com |
Earnings (1year) ($): | -3.71 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 3.44 |
Cash Flow ($): | -2.53 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | n/a |
Price/Book (x): | 3.11 |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 4.08 |
---|---|
Current Ratio (x): | 4.08 |
LT Debt/Equity (x): | 22.89 |
Total Debt/Equity (x): | 28.30 |